デフォルト表紙
市場調査レポート
商品コード
1226743

細胞増殖キットの世界市場:現状分析と予測(2022年~2028年)

Cell Proliferation Kit Market: Current Analysis and Forecast (2022-2028)

出版日: | 発行: UnivDatos Market Insights Pvt Ltd | ページ情報: 英文 142 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.54円
細胞増殖キットの世界市場:現状分析と予測(2022年~2028年)
出版日: 2023年01月01日
発行: UnivDatos Market Insights Pvt Ltd
ページ情報: 英文 142 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

世界の細胞増殖キットの市場規模は、予測期間中に約7%のCAGRで成長すると予測されています。がんや腫瘍の患者数の増加、早期診断の増加、医療費負担を軽減するための政府の取り組みの増加、医療に対する意識の高まりは、市場の成長を促進しています。

当レポートでは、世界の細胞増殖キット市場について調査しており、市場の洞察、市場動向、競合シナリオ、企業概要など、包括的な情報を提供しています。

目次

第1章 市場イントロダクション

  • 市場の定義
  • 主な目標
  • ステークホルダー
  • 制限

第2章 調査手法または仮定

  • 細胞増殖キット市場の調査プロセス
  • 細胞増殖キット市場の調査手法
  • 回答者プロファイル

第3章 市場要約

第4章 エグゼクティブサマリー

第5章 COVID-19が細胞増殖キット市場に与える影響

第6章 世界の細胞増殖キット市場の収益(2022年~2028年)

第7章 市場の洞察:タイプ別

  • 蛍光細胞生存キット
  • 比色細胞生存キット
  • 生物発光細胞生存キット
  • その他

第8章 市場の洞察:用途別

  • 製薬・バイオテクノロジー企業
  • 学術・研究機関
  • その他

第9章 市場の洞察:地域別

  • 北米
    • 米国
    • カナダ
    • その他の北米
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • スペイン
    • イタリア
    • その他の欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • オーストラリア
    • その他のアジア太平洋地域
  • その他

第10章 細胞増殖キットの市場力学

  • 市場促進要因
  • 市場の課題
  • 影響分析

第11章 細胞増殖キットの市場機会

第12章 細胞増殖キットの市場動向と洞察

第13章 需要側と供給側の分析

  • 需要側分析
  • 供給側分析

第14章 バリューチェーン分析

第15章 価格分析

第16章 戦略的洞察

第17章 競合シナリオ

  • 競合情勢
    • ポーターのファイブフォース分析

第18章 企業概要

  • Thermo Fisher Scientific Inc
  • Merck KGaA
  • GE Healthcare
  • PerkinElmer Inc
  • Bio-Rad Laboratories, Inc.
  • Becton Dickinson and Co
  • Biotium
  • Agilent Technologies Inc
  • F. Hoffmann-La Roche AG
  • Biological Industries

第19章 免責事項

目次
Product Code: UMME211630

The cell proliferation kit market is expected to register a CAGR of approx. 7% over the period of 2022-2028. Cell replication, or the process of cell proliferation, is essential for maintaining the homeostasis of adult tissues by replacing dead cells with fresh ones. This process begins during embryogenesis. Abnormal cell proliferation is seen in a few disease conditions, such as cancer. So, in both in vitro and in vivo settings, cell proliferation assay kits gained popularity in the clinical diagnosis of various disease indications. These are used in research studies of cell activation, cytotoxicity assessment, and clinical trials to determine therapeutic efficacy. The growing demand for cell proliferation kits can be attributed to the rising numbers of patients with cancer and tumors across the globe. For instance, according to the World Health Organization, Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. In 2021, there will be an estimated 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in the United States. Owing to the glaring statistics the rising prevalence of cancer leads to higher demand for cell proliferation kits across the globe and would contribute to the growth of the market in the forthcoming period as well. Furthermore, the cell proliferation kit market is anticipated to grow on account of the increasing number of early diagnostic procedures. In addition, the rise in government initiatives to control the healthcare burden and growing healthcare awareness among people drive market growth. However, some of the restraints in the market including the high cost of kits and lack of trained professionals are impeding the growth of this market all over the world.

Based on the type, the cell proliferation kit market is segmented into fluorometric cell viability kits, colorimetric cell viability kits, bioluminescent cell viability kits, and others. The colorimetric cell viability kits segment accounted for a significant market share in 2020 and it is estimated that it will grow rapidly during the projected timeframe. This method for detecting cell viability is cost-effective and easy to retrieve throughout data. It is also anticipated that the widespread use of this technique to identify various cellular activities, such as DNA synthesis, metabolic activity, and ATP production, will spur the expansion of the future market segment.

Based on the application, the market is fragmented into pharmaceutical and biotechnology companies, academic institutes and research laboratories, and others. The pharmaceutical and biotechnology companies segment grabbed a considerable market share and is expected to grow at a significant CAGR during the forecast period. Cell proliferation kits are used in academic institutions and research labs to identify cell damage by monitoring how the cells respond to various stimuli, such as hydrogen peroxide, antibiotics, etc.

For a better understanding of the market adoption of the cell proliferation kit, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, France, Italy, Spain, U.K., and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. North America constitutes a major market for the cell proliferation kit industry owing to the growing number of new cancer cases like melanoma, urothelial carcinoma, lung cancer, and others each year in the region. Moreover, the presence of well-established healthcare facilities, growing advanced technologies, as well as rising healthcare spending boost the market growth in this region. For instance, according to the centers for Medicare & Medicaid services, U.S. healthcare spending grew 2.7% in 2021, reaching USD 4.3 trillion or USD 12,914 per person. As a share of the nation's Gross Domestic Product, health spending accounted for 18.3%.

Some of the major players operating in the market include: Thermo Fisher Scientific Inc, Merck KGaA, GE Healthcare, PerkinElmer Inc, Bio-Rad Laboratories, Inc., Becton Dickinson and Co, Biotium, Agilent Technologies Inc, F. Hoffmann-La Roche AG, and Biological Industries, among others. Several M&As along with partnerships have been undertaken.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

  • 1.1. Market Definitions
  • 1.2. Main Objective
  • 1.3. Stakeholders
  • 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

  • 2.1. Research Process of the Cell Proliferation Kit Market
  • 2.2. Research Methodology of the Cell Proliferation Kit Market
  • 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE CELL PROLIFERATION KIT MARKET

6 GLOBAL CELL PROLIFERATION KIT MARKET REVENUE, 2020-2028F

7 MARKET INSIGHTS BY TYPE

  • 7.1. Fluorometric Cell Viability Kits
  • 7.2. Colorimetric Cell Viability Kits
  • 7.3. Bioluminescent Cell Viability Kits
  • 7.4. Others

8 MARKET INSIGHTS BY APPLICATION

  • 8.1. Pharmaceutical and Biotechnology Companies
  • 8.2. Academic Institutes and Research Laboratories
  • 8.3. Others

9 MARKET INSIGHTS BY REGION

  • 9.1 NORTH AMERICA CELL PROLIFERATION KIT MARKET
    • 9.1.1 U.S.
    • 9.1.2 Canada
    • 9.1.3 Rest of North America
  • 9.2 EUROPE CELL PROLIFERATION KIT MARKET
    • 9.2.1 Germany
    • 9.2.2 France
    • 9.2.3 U.K.
    • 9.2.4 Spain
    • 9.2.5 Italy
    • 9.2.6 Rest of Europe
  • 9.3 ASIA PACIFIC CELL PROLIFERATION KIT MARKET
    • 9.3.1 China
    • 9.3.2 Japan
    • 9.3.3 India
    • 9.3.4. Australia
    • 9.3.4 Rest of Asia Pacific
  • 9.4 REST OF WORLD CELL PROLIFERATION KIT MARKET

10 CELL PROLIFERATION KIT MARKET DYNAMICS

  • 10.1 Market Drivers
  • 10.2 Market Challenges
  • 10.3 Impact Analysis

11 CELL PROLIFERATION KIT MARKET OPPORTUNITIES

12 CELL PROLIFERATION KIT MARKET TRENDS & INSIGHTS

13 DEMAND AND SUPPLY SIDE ANALYSIS

  • 13.1 Demand Side Analysis
  • 13.2 Supply Side Analysis

14 VALUE CHAIN ANALYSIS

15 PRICING ANALYSIS

16 STRATEGIC INSIGHTS

17 COMPETITIVE SCENARIO

  • 17.1. Competitive Landscape
    • 17.1.1 Porter's Five forces analysis

18 COMPANY PROFILED

  • 18.1. Thermo Fisher Scientific Inc
  • 18.2. Merck KGaA
  • 18.3. GE Healthcare
  • 18.4. PerkinElmer Inc
  • 18.5. Bio-Rad Laboratories, Inc.
  • 18.6. Becton Dickinson and Co
  • 18.7. Biotium
  • 18.8. Agilent Technologies Inc
  • 18.9. F. Hoffmann-La Roche AG
  • 18.10. Biological Industries

19 DISCLAIMER